GlassScriptPhysician profile
Claudia P Angel
NPI 1215108113
$3,202.84
in general payments reported to CMS, 2019-2025
16 companies · $754 in 2025
The $754 reported for 2025 was more than what 78% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $130 · 2022: $479 · 2023: $825 · 2024: $1,016 · 2025: $754.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,589 · Education: $5.14.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,589.14 |
| Education | $5.14 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alkermes, INC. | $646.71 | 2021-2025 | Lybalvi, Vivitrol, Vivitrol |
| Teva Pharmaceuticals USA, INC. | $556.64 | 2022-2025 | Uzedy, Austedo |
| E.R. Squibb & Sons, L.L.C. | $262.05 | 2025 | Cobenfy |
| Braeburn INC. | $229.81 | 2024-2025 | Brixadi |
| Novo Nordisk INC | $225.24 | 2024 | Wegovy |
| Neurocrine Biosciences, INC. | $208.92 | 2023 | Ingrezza |
| Abbvie INC. | $199.14 | 2023-2024 | |
| Janssen Pharmaceuticals, INC | $158.70 | 2022-2024 | Invega Trinza, Invega Sustenna |
| Otsuka America Pharmaceutical, INC. | $148.84 | 2025 | Abilify Asimtufii, Abilify Maintena |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $130.13 | 2023 | |
| Gilead Sciences, INC. | $116.10 | 2024 | Epclusa |
| Astrazeneca Pharmaceuticals LP | $99.99 | 2022 | |
| Alnylam Pharmaceuticals INC. | $95.96 | 2023 | Givlaari |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $90.00 | 2024 | Xifaxan |
| Vanda Pharmaceuticals INC. | $19.23 | 2024 | Fanapt |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Acadia Pharmaceuticals INC | $15.38 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Claudia Angel listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.